Sudler and Hennessey wins the Novo Nordisk and Glaxo SmithKline businesses

Sudler and Hennesey India – the joint venture between Sudler and Hennessey International and Rediffusion DY&R – has bagged two new accounts.

The two new accounts are the insulin business of Novo Nordisk and two of the variants of Glaxo SmithKline, Feronine (an iron supplement for pregnant women) and Zodactin (an antibiotic).

Speaking to agencyfaqs!, Asha Kapoor, executive director, Sudler and Hennessey, says, “We have won all these accounts following multi-agency pitches. We work for the pharmaceutical part of the industry, which calls for a great degree of responsibility. Since all these products belong to the Rx category, the communications will be designed only for doctors.”

Kapoor adds, “The campaign will include various scientific modes of communication such as scientific literature, compendiums and visual aids.”

Novo Nordisk has introduced products and generated awareness in India pertaining to diabetes and its treatment. On the other hand, Glaxo SmithKline is a research-based healthcare and pharmaceutical company, which has launched various pharmaceutical products in India.

© 2005 agencyfaqs!